Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 562 Carcinoma, Non-Small-Cell Lung 482 Ovarian Neoplasms 326 Lung Neoplasms 203 Fallopian Tube Neoplasms 152 Neoplasms 150 Triple Negative Breast Neoplasms 125 Esophageal Neoplasms 125 Stomach Neoplasms 121 Neoplasm Metastasis 119 Carcinoma, Ovarian Epithelial 114 Endometrial Neoplasms 95 Squamous Cell Carcinoma of Head and Neck 94 Uterine Cervical Neoplasms 79 Head and Neck Neoplasms 77 Esophageal Squamous Cell Carcinoma 77 Recurrence 48 Adenocarcinoma of Lung 47 Parkinson Disease 4, Autosomal Dominant Lewy Body 45 Melanoma 42 Carcinoma 42 Urinary Bladder Neoplasms 41 Adenocarcinoma Of Esophagus 36 Small Cell Lung Carcinoma 34 Carcinoma, Squamous Cell 34 Prostatic Neoplasms 31 Pancreatic Neoplasms 29 Breast Neoplasms, Male 28 Unspecified Adult Solid Tumor, Protocol Specific 27 Colorectal Neoplasms 25

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Malignant Disease × Paclitaxel × Clear all

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡